Clinical Prophylaxis

View All Members
Dr. Johnny Mahlangu
MBBCh, MMed, FCPath

Dr. Johnny Mahlangu is an accredited clinical hematologist with over 50 peer-reviewed papers, abstracts and presentations in 2018 alone. He is a part of numerous national and international leadership positions in groups that are dedicated to the advancement of haemophilia treatment around the world

Key Publications

  Johnny Mahlangu. Emicizumab for prevention of bleeds in Haemophilia. Expert Biological Therapies 2019 Jun 13:1-9

    Johnny Mahlangu, Johannes Oldenburg, Michael Callaghan, Midori Shima, Maria Elisa Mancuso,  Peter Trask, Michael Recht, Claudia Garcia, Ranchi Yang, Michaela Lehle, Harrison Macharia, Elina Ascanius, Gallia G. Levy,6 Rebecca Kruse-Jarres, Sylvia von Mackensen. Health-Related Quality Of Life and Health Status In Persons With Haemophilia A With Inhibitors: A Prospective, Multicenter, Non-Interventional Study (NIS)- Haemophilia 2019 May;25(3):382-391

    Johnny Mahlangu. Update on extended Half life FIX products. Ther Adv Hematol. 2018 Oct 5;9(11):335-346

    Johnny Mahlangu, Johannes Oldenburg, Ido Paz-Priel, Claude Negrier, Markus Niggli, Maria Elisa Mancuso, Christophe Schmitt, Victor-Jiménez Yuste, Christine Kempton, Christophe Dhalluin, Michael Callaghan, Willen Bujan, Midori Shima, Elina Asikanius, Gallia G. Levy, Rebecca Kruse-Jarres- Emicizumab Prophylaxis in Hemophilia A without Inhibitors- Study NEJM 2018, 379(9): 811-22

    Johnny Mahlangu, Monica Cerqueira, Alok Srivastava. Emerging therapies- a Global Perspective.Haemophilia. 2018;24(Suppl. 6):15–21

Current Positions/Chairs:

  • Professor of Haematology
    University of Witwatersrand
  • Head of School of Pathology
    Faculty of Health Sciences, University of Witwatersrand
  • Head of Clinical Haematology Ward and Clinical Service
    Charlotte Maxeke Johannesburg Academic Hospital
  • Head of the Main Haematology Diagnostic Section
    Department of Molecular Medicine and Haematology, National Health Laboratory Service Haematology Laboratory
  • Director
    WFH International Training Centre, Johannesburg
  • Director
    Bleeding Disorders Unit/ Haemophilia Comprehensive Care Centre- Charlotte Maxeke Johannesburg Academic Hospital
  • Director
    Clinical Haematology Research Unit, Wits Health Consortium, Parktown, Johannesburg
  • Accredited Clinical Haematologist
    Wits Donald Gordon Medical Centre, Parktown, Johannesburg

Key Institutions

  • University of Witwatersrand
    Department of Haematology
    South Africa
  • Charlotte Maxeke Johannesburg Academic Hospital
    Clinical Haematology Ward and Clinical Service
    South Africa
  • National Health Laboratory Service Haematology Laboratory
    Department of Molecular Medicine and Haematology
    South Africa
  • Witts Health Consortium
    Clinical Haematology Research Unit
    South Africa

Research Interests

  • Dr. Mahlangu’s interests lie in research and development of innovative therapies in bleeding disorders.
  • He has conducted over 70 international studies including major studies in the evolution of current haemophilia therapies.

Achievements

  • South African National Research Foundation B rating (2018)
  • Faculty of Health Sciences Honors Celebration Special Recognition (2018)
  • Colleges of Medicine of South Africa Triennium Service Recognition Certificate (2018)
  • University of Witwatersrand Vice Chancellor Academic Citizenship award (2018)
  • Fellow of the Academy of Medicine of Malaysia(2018)